Description: <p><b>Andrographis</b> — Andrographis (typically <i>Andrographis paniculata</i>, “King of Bitters”) is a bitter medicinal plant whose principal bioactive diterpenoid lactone is <b>andrographolide</b> (with related diterpenoids such as neoandrographolide). It is best classified as a <b>botanical drug / phytochemical mixture</b> (plant extract) with a dominant small-molecule active. Common abbreviation(s): <b>AP</b> (plant), <b>AND</b> (andrographolide). The best-supported pharmacology in humans is anti-inflammatory/immunomodulatory use (e.g., URTI symptom reduction), while oncology relevance is predominantly preclinical, with frequent reporting of NF-κB/STAT3/PI3K-AKT pathway suppression and downstream effects on proliferation, apoptosis, invasion, and angiogenesis.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>NF-κB inflammatory/survival transcription inhibition (context-dependent upstream hub for cytokines, COX-2, anti-apoptotic programs)</li>
<li>JAK/STAT3 pathway suppression (oncogenic transcription and inflammatory reinforcement loop)</li>
<li>PI3K–AKT–mTOR axis suppression (growth/survival signaling; often downstream of inflammatory signaling changes)</li>
<li>Stress MAPK reprogramming (JNK/p38 frequently ↑; ERK effects mixed by model/dose)</li>
<li>Cell-cycle checkpoint enforcement (G0/G1 or G2/M arrest; cyclins/CDKs ↓; p21 ↑)</li>
<li>Mitochondrial apoptosis execution (BAX↑, Bcl-2↓, caspases↑; MMP↓)</li>
<li>Anti-invasive/anti-EMT effects (MMP2/9↓; migration/invasion ↓)</li>
<li>Anti-angiogenic signaling suppression (VEGF↓; HIF-1α↓ reported in some models)</li>
<li>Redox and ferroptosis-linked modulation (ROS ↔; NRF2↑ in some contexts; xCT↓/GPX4↓/iron↑ reported in some tumor models)</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Oral exposure of andrographolide from extracts is highly formulation-dependent and often low; even at high oral regimens used clinically (e.g., extract equivalents targeting ~180–360 mg/day andrographolide), measured plasma concentrations can remain in the low ng/mL range and may show non-linear dose proportionality. This creates a translation gap for many oncology in-vitro concentrations unless delivery is optimized (e.g., solubility enhancement, lipid/polymer carriers, prodrugs).</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Many reported anticancer effects occur at micromolar in-vitro levels that commonly exceed achievable free systemic concentrations after standard oral supplementation; therefore, “direct cytotoxic” interpretations are frequently exposure-limited, while anti-inflammatory signaling modulation may be more plausibly aligned with in-vivo exposures depending on tissue distribution and formulation.</p>
<p><b>Clinical evidence status:</b> Human clinical evidence is strongest for infectious/inflammatory indications (URTI symptom reduction; studied in COVID-19-era settings with mixed outcomes and safety monitoring). For oncology, evidence is <b>primarily preclinical</b>, with limited registered/early clinical exploration and no established standard anticancer indication.</p>
<br
<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4032030/">"used traditionally for the treatment of array of diseases such as cancer, diabetes, high blood pressure, ulcer, leprosy, bronchitis, skin diseases, flatulence, colic, influenza, dysentery, dyspepsia and malaria for centuries in Asia, America and Africa continents."</a><br>
<br>
Andrographolide:<br>
– Is a specific diterpenoid lactone and the major active constituent extracted from Andrographis paniculata.<br>
– It is responsible for many of the therapeutic effects attributed to the plant, including anti-inflammatory and antioxidant properties.<br>
<br>
A. Anti-Inflammatory Effects.<br>
• Andrographolide has been shown to inhibit the NF-κB pathway, leading to a reduction in the transcription of inflammatory cytokines (e.g., TNF-α, IL-6).<br>
• Andrographolide has been reported to cause cell cycle arrest at critical checkpoints (such as G0/G1 or G2/M phase) in some cancer cell models.<br>
<br>
Andrographis, primarily through its active constituent andrographolide, offers compelling anti-inflammatory, immunomodulatory, pro-apoptotic, and antiproliferative properties. While not a standard anticancer agent, its capacity to modulate key pathways in cellular stress response and inflammation makes it an attractive candidate for complementary research in oncology.<br>
<br>
Andrographis paniculata, also known as the "King of Bitters," is a plant native to India and Southeast Asia. Its aqueous extract, Andrographis paniculata aqueous extract (APAE), has been studied for its potential anti-cancer properties.<br>
• Inhibition of cancer cell growth: APAE has been shown to inhibit the growth of various cancer cell lines, including breast, lung, colon, and prostate cancer cells.<br>
• Induction of apoptosis: APAE has been found to induce apoptosis (programmed cell death) in cancer cells, which may help to prevent tumor growth and progression.<br>
• Anti-inflammatory effects: APAE has anti-inflammatory properties, which may help to reduce the risk of cancer development and progression.<br>
• Antioxidant activity: APAE has antioxidant activity, which may help to protect against oxidative stress and DNA damage.<br>
<br>
Key compounds:Andrographolide, Neoandrographolide<br>
APAE may interact with certain medications, including blood thinners and diabetes medications, and may not be suitable for individuals with certain medical conditions, such as autoimmune disorders.<br>
<br>
<h3>Andrographis (A. paniculata / andrographolide) — ranked mechanistic axes in oncology context</h3>
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>NF-κB inflammatory and survival transcription</td>
<td>NF-κB ↓; COX-2 ↓; IL-6/TNF-α ↓; anti-apoptotic programs ↓ (model-dependent)</td>
<td>Inflammatory tone ↓</td>
<td>R, G</td>
<td>Anti-inflammatory and anti-survival transcription</td>
<td>Most consistently reported hub mechanism across models; often upstream of invasion/angiogenesis phenotypes.</td>
</tr>
<tr>
<td>2</td>
<td>JAK/STAT3 signaling</td>
<td>STAT3 activation ↓ (model-dependent)</td>
<td>↔</td>
<td>R, G</td>
<td>Oncogenic transcription suppression</td>
<td>Commonly linked to reduced proliferation, survival, and inflammatory reinforcement loops.</td>
</tr>
<tr>
<td>3</td>
<td>PI3K AKT mTOR axis</td>
<td>PI3K/AKT ↓; mTOR ↓ (model-dependent)</td>
<td>↔</td>
<td>R, G</td>
<td>Growth and survival constraint</td>
<td>Often reported as downstream of inflammatory signaling changes; leverage depends on achievable exposure.</td>
</tr>
<tr>
<td>4</td>
<td>MAPK stress signaling</td>
<td>JNK ↑ and p38 ↑ common; ERK ↔ (dose-dependent)</td>
<td>↔</td>
<td>P, R, G</td>
<td>Stress-response reprogramming</td>
<td>Pattern often resembles a pro-stress shift enabling checkpointing/apoptosis; ERK effects vary by context.</td>
</tr>
<tr>
<td>5</td>
<td>Cell-cycle checkpoints</td>
<td>Arrest ↑ (G0/G1 or G2/M); Cyclin D1/CDKs ↓; p21 ↑ (model-dependent)</td>
<td>↔</td>
<td>G</td>
<td>Cytostasis</td>
<td>Frequently described alongside NF-κB/STAT3 suppression; may dominate at sub-cytotoxic exposure.</td>
</tr>
<tr>
<td>6</td>
<td>Mitochondria and intrinsic apoptosis</td>
<td>MMP ↓; Bax ↑; Bcl-2 ↓; caspases ↑ (model-dependent)</td>
<td>↔</td>
<td>G</td>
<td>Apoptotic execution</td>
<td>Downstream of survival pathway inhibition and stress signaling; extent often concentration-limited in vivo.</td>
</tr>
<tr>
<td>7</td>
<td>Redox and NRF2</td>
<td>ROS ↑ or ↓ (context-dependent); NRF2 ↑ (some models)</td>
<td>Antioxidant and anti-inflammatory bias in non-cancer contexts</td>
<td>P, R, G</td>
<td>Redox modulation</td>
<td>Bidirectional redox effects are common in phytochemicals; interpret as context- and dose-dependent rather than a single-direction mechanism.</td>
</tr>
<tr>
<td>8</td>
<td>Ferroptosis-linked axis</td>
<td>xCT ↓; GPX4 ↓; iron handling ↑; lipid peroxidation ↑ (model-dependent)</td>
<td>↔</td>
<td>R, G</td>
<td>Non-apoptotic vulnerability induction</td>
<td>Reported in some tumor models; translation depends on whether these targets are engaged at achievable exposure.</td>
</tr>
<tr>
<td>9</td>
<td>Invasion EMT MMP program</td>
<td>MMP2 ↓; MMP9 ↓; migration and invasion ↓ (model-dependent)</td>
<td>↔</td>
<td>G</td>
<td>Anti-metastatic phenotype support</td>
<td>Commonly framed as secondary to NF-κB/STAT3 suppression.</td>
</tr>
<tr>
<td>10</td>
<td>Angiogenesis and hypoxia signaling</td>
<td>VEGF ↓; HIF-1α ↓ (model-dependent)</td>
<td>↔</td>
<td>G</td>
<td>Anti-angiogenic support</td>
<td>Typically downstream/secondary; strength depends on tumor model and exposure.</td>
</tr>
<tr>
<td>11</td>
<td>Clinical Translation Constraint</td>
<td>Oral bioavailability low and formulation-dependent; plasma levels often far below many in-vitro oncology concentrations; non-linear PK at high-dose extracts</td>
<td>Monitoring needed in higher-dose use</td>
<td>—</td>
<td>Translation constraint</td>
<td>High-dose extract PK in humans shows low ng/mL exposure and potential liver enzyme elevations at higher regimens; oncology use remains investigational.</td>
</tr>
</table>
<p><b>TSF</b> legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr</p>